SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to represent SpaceX, with many warning it is a scam while others speculate on its connection to the company's long-rumored IPO. The community conversation is dominated by intense skepticism regarding unauthorized tokens, contrasted with broader market excitement surrounding SpaceX's expected public debut and its potential impact on space-sector stocks.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors highlight its role as an AI-powered infrastructure project on the Base ecosystem, with community members actively discussing its long-term potential as an undervalued asset. The sentiment is fueled by consistent development updates from the team and strong ecosystem volume, leading many to hold through market volatility in anticipation of future price appreciation.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors weigh its potential as a vertically integrated domestic rare earth magnet manufacturer against concerns regarding its micro-float and high insider ownership. Community discussion is split between excitement over the stock's positioning as a strategic alternative to foreign supply chains and caution regarding its characteristic high volatility and potential for sharp price swings.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

The community is actively discussing $DEGEN, pointing to a mix of optimism surrounding potential exchange listings and a new beta app while others express frustration over token performance. Investors remain hyper-focused on upcoming project catalysts and social media branding as they debate whether the token is currently at a critical accumulation phase.

Ideal Power, Inc. engages in the development of power converter solutions for photovoltaic generation, grid-storage and electrified vehicle charging. Its products include solar inverters, bi-directional battery, electric vehicle chargers, photovoltaic inverters and battery converters. It is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. The company was founded by William C. Alexander on May 17, 2007 and is headquartered in Austin, TX.

Ideal Power Inc

Ideal Power is trending as investors monitor its progress in commercializing B-TRAN technology, highlighted by the early completion of its first major solid-state circuit breaker design win in Asia. The community is focused on the stock's potential for institutional adoption and institutional validation as it targets a multibillion-dollar market for power semiconductors in data centers, EVs, and renewable energy.

WW International, Inc. engages in the provision of weight management services. It operates through the following geographical segments: United States, Germany, and Other. The company was founded by Jean Nidetch in 1963 and is headquartered in New York, NY.

WW International Inc - Ordinary Shares - New

WW International, Inc. Common Stock

WW International is gaining traction as investors speculate on a turnaround driven by strategic partnerships with GLP-1 medication providers and debt-reduction efforts. The community remains divided, with some betting on a successful pivot toward clinical weight-loss solutions while others remain skeptical due to the company's historical financial struggles and competitive pressure.

Realty Income Corp. is a real estate company, which engages in generating dependable monthly cash dividends from a consistent and predictable level of cash flow from operations. The company was founded by William E. Clark, Jr. and Evelyn Joan Clark in 1969 and is headquartered in San Diego, CA.

Realty Income Corp.

Realty Income (O) remains a focal point for income-focused investors due to its consistent monthly dividend payouts and ongoing global expansion efforts. The community is actively debating the stock's long-term growth potential against macroeconomic headwinds, with many investors using recent price dips as opportunities to build positions ahead of anticipated interest rate adjustments.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the company's aggressive restructuring plan, including workforce reductions and the scaling back of Amazon-linked volume, against mounting competition from Amazon's own supply chain services. The community remains deeply divided, with some highlighting the stock as an undervalued dividend play while others express concerns over labor costs, margin pressures, and the long-term impact of Amazon's logistics expansion.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending as investors monitor institutional accumulation and signs of a potential short squeeze amid anticipation of profitability in the coming quarters. The community is actively discussing the drug's strong prescription growth and its long-term potential as an acquisition target for larger pharmaceutical firms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The German drugmaker will transfer select intellectual property to the new entity while retaining a minority stake.</li><li>The new entity will operate independently with its own financial structure, research agenda, and operational framework.</li><li>BioNTech will continue concentrating on its expanding late-stage development portfolio.</li></ul>BioNTech SE (BNTX) on Tuesday revealed plans to launch a separate biotechnology venture dedicated to advancing next-generation messenger RNA technologies, with the initiative to be led by its co-founders Ugur Sahin and Prof. Özlem Türeci, who are set to leave the company to head the new venture.&nbsp;&nbsp;The new entity will operate independently with its own financial structure, research agenda, and operational framework while collaborating with BioNTech in specific areas of development.Following the announcement, BioNTech stock tumbled nearly 17% in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h3>Founders Exit To Lead New mRNA Venture</h3>The Germany-based company intends to transfer certain intellectual property and technology assets tied to mRNA research to the new organization while retaining a minority ownership stake and potential milestone or royalty payments.The forthcoming company will concentrate exclusively on developing emerging mRNA platform technologies with potential medical applications.<h3>BioNTech Keeps Focus On Oncology Pipeline</h3>While the new venture focuses on experimental mRNA innovation, BioNTech will continue concentrating on its expanding late-stage development portfolio. The company expects around 15 Phase 3 clinical trials in oncology to be underway by the end of 2026.&nbsp;“We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients”.-Helmut Jeggle, Chairman, BioNTech Supervisory Board<h2 class="st-heading-2">Q4 Earnings Pressure&nbsp;</h2>BioNTech reported a 23% year-on-year (YoY) decline in fourth-quarter earnings to €907.4 million ($1.05 billion). Loss per share also widened to €1.25 from a loss per share of €0.33 last year.&nbsp;BNTX stock has declined by 3% in the last 12 months.&nbsp;Conversion Rate: €1=$1.16Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/att-250-billion-fiber-5g-network-investment-plan/cZdoY58RIew">AT&amp;T Is Spending $250B On Connectivity In The US – Here’s Where The Money Is Going</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech mRNA-based vaccine manufacturing site in Rwanda | Source: BioNTech

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  

Equity

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  


<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

AI Scare Back in the Market: ETFs That Stayed Steady

AI fears rattled markets as IBM sank and tech slid, but ETFs like OIH, BWET, IDNA and HDGE stayed resilient, gaining even as major indexes fell.

<ul class="summary-bullets"><li>Moderna has submitted a revised approach to streamline approval based on age-specific indications.</li><li>The company proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults 65 and older.</li><li>Last week, the FDA refused to review Moderna’s application for the flu vaccine.</li></ul>Moderna, Inc. (MRNA) said on Wednesday that it is moving forward with regulatory review for its investigational seasonal flu vaccine, mRNA-1010, after responding to a prior Refusal-to-File letter from the U.S. Food and Drug Administration (FDA).&nbsp;The company has submitted a revised approach to streamline approvals based on age-specific indications.<h2 class="st-heading-2">Targeted Approval Strategy</h2>Moderna proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older, along with a post-marketing study to further evaluate safety and efficacy in older populations.The FDA has now accepted the biologics license application (BLA) for review, setting a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 5, 2026.<blockquote>"Pending FDA approval, we look forward to making our flu vaccine available later this year so that America's seniors have access to a new option to protect themselves against flu."-Stéphane Bancel, CEO, Moderna</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> traded over 5% higher on Wednesday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_091941_png_316eca4dee.webp" alt="MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global Regulatory Progress</h2>mRNA-1010 has entered regulatory review not only in the U.S. but also in Europe, Canada, and Australia, with additional filings planned for later in 2026. Moderna anticipates the first potential approvals for the vaccine to occur within the year.If approved, mRNA-1010 would be available for U.S. adults aged 50 and above, including those 65 and older, for the 2026/2027 influenza season.&nbsp;Last week, the FDA refused to review Moderna’s application for the flu vaccine and cited the lack of an "adequate and well-controlled" study with a comparator arm that "does not reflect the best-available standard of care."&nbsp;MRNA stock has gained over 28% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/walmart-earnings-can-wmt-stock-sustain-momentum-under-new-ceo/cZR0ZxRR4Hs">Walmart Earnings Ahead: Can WMT Stock Sustain Momentum Under New CEO?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

<ul class="summary-bullets"><li>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following subcutaneous administration.</li><li>Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients.</li><li>The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.</li></ul>Alvotech (ALVO) shares were up nearly 10% in Thursday’s pre-market trade after the company announced positive top-line results from its pharmacokinetic study.The company stated that the study showed that AVT80, its biosimilar candidate to Entyvio, met all its primary endpoints.“We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions,” said Alvotech COO Joseph McClellan.<h2 class="st-heading-2">Details Of The Pharmacokinetics Study</h2>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following a single 108 mg/0.68 mL subcutaneous (SC) injection.Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients. The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.Alvotech also stated that it is currently developing AVT16, a proposed biosimilar to Entyvio for intravenous administration, while AVT80 is designed for subcutaneous administration.The Pharmacokinetic study for AVT80 is crucial to demonstrating clinical similarity between AVT16 and AVT80, the company added.<h2 class="st-heading-2">What Does Alvotech Do?</h2>Alvotech is a Reykjavik, Iceland-based biotechnology company that is focused exclusively on developing biosimilar medicines.The company has two biosimilars, Humira and Stelara, already approved and marketed in multiple markets around the world. Alvotech has partnered with multiple companies globally, including Teva Pharmaceuticals, Cipla, Dr. Reddy’s, and Lotus Pharmaceuticals, among others.&nbsp;<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ALVO">Alvotech</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels. The ALVO ticker was the fourth most trending ticker on the platform at the time of writing.One bullish user called the top-line results “huge news” for Alvotech.<stembedurl>https://stocktwits.com/NewsTrader_perform4nce/message/644068023</stembedurl><a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 1% year-to-date and 59% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-excellent-call-with-china-xi-jinping-trip-in-april/cZbj5hCR4Z6">Trump Announces He Had An ‘Excellent’ Call With Chinese President Xi Jinping, Says He Will Travel In April To China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alvotech logo is seen displayed on a smartphone screen

Why Is ALVO Stock Rising Pre-Market Today?

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

Current Price	$28.81
Prev Close	$29.54
Open	$29.34
Dividend Yield	N/A
50-Day Moving Average	$29.53
Beta	N/A
Avg. Volume	43,430.83
PE Ratio	N/A

52-Week High	$31.41
52-Week Low	$19.74
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IDNA
iShares Genomics Immunology and Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IDNA News

IDNAiShares Genomics Immunology and Healthcare ETF